This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Strand, V Search for Related Content PubMed PubMed Citation Articles by Strand, V Pubmed/NCBI databases Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Monoclonal antibodies and other biologic therapies

Division of Immunology, Clinical Faculty, Stanford University School of Medicine, Palo Alto, CA, USA; 306 Ramona Road, Portola Valley, CA 94028, USA. Tel: +1 650 529 0150; Fax: +1 650 529 0225,vstrand{at}aol.com

The treatment of systemic lupus erythematosus (SLE) presents a significant therapeutic challenge: multi-organ involvement and a variable disease course characterized by clinical exacerbations and remissions make it difficult to predict outcome. Few products have been specifically developed in this clinical indication and most accepted therapies have not been tested in randomized controlled trials in SLE. A variety of biologic agents under investigation as potential treatments for SLE are designed to interfere with specific immunologic responses, hopefully avoiding gneralized immunosuppression. These include therapies to downregulate IL-10 and/or upregulate TGFb production. Agents which interfere with T cell activation and T cell–B cell collaboration, such as CTLA4-Ig and anti-CD40 ligand monoclonal antibodies, may result in long term therapeutic benefit; alone or in combination, even following brief treatment courses. Products designed to decrease production of anti-dsDNA antibodies or inhibit complement activation may prevent immune complex deposition and amerliorate organ-specific manifestations such as renal disease. More aggressive interventions include gene therapy and stem cell transplantation. As these agents enter clinical trials, efforts to develop international consensus regarding trial methodology and outcome measures will be crucial to their successful development.

Key Words: SLE • biologic therapies • monoclonalantibodies

Lupus, Vol. 10, No. 3, 216-221 (2001)
DOI: 10.1191/096120301669817290


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D Micheloud, L Nuno, M Rodriguez-Mahou, S Sanchez-Ramon, M C Ortega, A Aguaron, E Junco, J Carbone, E Fernandez-Cruz, L Carreno, et al. Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy Lupus, December 1, 2006; 15(12): 881 - 885. [Abstract] [PDF]

				S Vasoo and G R. Hughes Theory, targets and therapy in systemic lupus erythematosus Lupus, March 1, 2005; 14(3): 181 - 188. [Abstract] [PDF]

				H Tahir and D A Isenberg Novel therapies in lupus nephritis Lupus, January 1, 2005; 14(1): 77 - 82. [Abstract] [PDF]

				F Falcini Vascular and connective tissue diseases in the paediatric world Lupus, February 1, 2004; 13(2): 77 - 84. [Abstract] [PDF]